The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The SeaLAND study: lenalidomide ± selinexor as maintenance post-autoSCT in newly diagnosed myeloma
Matthew Rees, MD, St. Vincent’s Hospital, Melbourne, Australia, presents the findings from the primary analysis of the Phase III SeaLAND (ALLG MM23) study (ACTRN12620000291987), a randomized trial comparing selinexor plus lenalidomide to lenalidomide alone as maintenance therapy following autologous stem cell transplantation (autoSCT) in newly diagnosed multiple myeloma (MM). Dr Rees highlights that adding low-dose selinexor to lenalidomide maintenance did not improve progression-free survival (PFS) and that, although a higher complete response (CR) rate was observed with the combination arm, this came at the cost of increased toxicity. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
